Skip to main content
Christopher Sweeney, MD, Oncology, Boston, MA, Dana-Farber Cancer Institute

ChristopherJSweeneyMD

Oncology • Boston, MA

Associate Professor, Medicine-Brigham & Women's Hospital, Harvard Medical School

Join to view full profile

Dr. Sweeney is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Sweeney's full profile

Already have an account?

Education & Training

  • Indiana University School of Medicine
    Indiana University School of MedicineFellowship, Hematology and Medical Oncology, 1997 - 2001
  • Gundersen Lutheran Medical Foundation
    Gundersen Lutheran Medical FoundationResidency, Internal Medicine, 1994 - 1997
  • The University of Adelaide Faculty of Health Sciences
    The University of Adelaide Faculty of Health SciencesClass of 1993

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2009 - 2024
  • WI State Medical License
    WI State Medical License 1997 - 2001
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • A Dose Finding Clinical Trial of Cabozantinib (XL184) Administered in Combination with Abiraterone Acetate in Metastatic Castration‐Resistant Prostate Cancer  
    Christopher Sweeney, Lauren C Harshman, Mark Pomerantz, Brandon Bernard, Atish D Choudhury, Philip W Kantoff, The Prostate
  • Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration  
    Richard S Foster, Lawrence H Einhorn, Christopher J Sweeney, Guru Sonpavde, Costantine Albany, Chandra K Flack, The Journal of Urology

Lectures

  • Overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Phase 1b/2 study of enzalutamide (ENZ) with LY3023414 (LY) or placebo (PL) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) after progres... 
    2019 ASCO Annual Meeting - 6/1/2019

Authored Content

  • Having Found Meaningful Intermediate Prostate Cancer Clinical Endpoints Associated with Overall Survival, What Next?July 2018

Press Mentions

  • 7 Sneaky Signs of Testicular Cancer
    7 Sneaky Signs of Testicular CancerApril 29th, 2022
  • UT Student Diagnosed with Testicular Cancer at 17 Years Old Shares Story to Educate Others
    UT Student Diagnosed with Testicular Cancer at 17 Years Old Shares Story to Educate OthersApril 28th, 2021
  • How Has the Covid-19 Pandemic Impacted Cancer Research?
    How Has the Covid-19 Pandemic Impacted Cancer Research?January 13th, 2021
  • Join now to see all

Grant Support

  • Evaluating A Parthenolide Analogue As A New Bladder And Kidney Cancer TherapyNational Cancer Institute2011–2012
  • Phase I, Pharmacokinetic, Pharmacodynamic Trial Of PTK787 And Paclitaxel In CNational Center For Research Resources2006–2008
  • A Pharmacokinetic And Pharmacogenetic Study Of ChemotherapeuticNational Center For Research Resources2006–2008
  • Phase I Dose Escalation Study To Determine The Safety,Pharmacokinetics AndNational Center For Research Resources2006
  • A Phase I Study Of OSI-461 In Combination With Mitoxantrone (Novantrone ) InNational Center For Research Resources2006
  • A Phase 1 Safety And Pharmacokinetic Study Of Su011248 And Capecitabine In PANational Center For Research Resources2006
  • OSI-774 In Combo W/Weekly Docetaxel In PTS W/Taxane Naive MalignanciesNational Center For Research Resources2004–2006

Hospital Affiliations

Dr. Christopher Sweeney, Dr. Christopher Sweeney, MD, Dr. C Sweeney, Dr. Christopher J Sweeney